How does adding PD-(L)1 inhibitors to platinum-etoposide treatment of small cell lung cancer improve survival outcomes? | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Efficacy and safety of first-line PD-L1/PD-1 inhibitors in limited-stage small cell lung cancer: a multicenter propensity score matched retrospective study2024 · 9 citations
2Older adults with extensive-stage small-cell lung cancer treated with first-line chemoimmunotherapy: Updated systematic review and meta-analysis.Meta-Analysis · 2026
3Clinical outcomes of PD-1 versus PD-L1 inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A propensity score–matched study.Human Clinical Trial · 2026
4Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A propensity score-matched study.2024 · 1 citations
5Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A propensity score-matched study.2024
6First-line immunotherapy plus chemotherapy for ES-SCLC: Comparison between PD-1 and PD-L1 inhibitors in a real-world setting.2024
7Efficacy and safety of PD-1/PD-L1 inhibitor-combined chemotherapy versus chemotherapy alone in extensive-stage small-cell lung cancer: a meta-analysisRCT · 2026 · 1 citations
8Beyond-line immunotherapy in ES-SCLC: Efficacy and safety of second-line PD-1/PD-L1 inhibitors after progression on first-line PD-1/PD-L1 inhibitors plus platinum-etoposide chemotherapy.Human Clinical Trial · 2026
9Trastuzumab deruxtecan in HER2-expressing urothelial carcinoma: current evidence, biomarker challenges, and future therapeutic strategiesExpert Review of Anticancer Therapy · 2026
10Biological state–guided oncology: a framework for dynamic precision cancer care through oncological state transitionsExpert Review of Anticancer Therapy · 2026

More from Expert Review of Anticancer Therapy

More from University of Bologna